 |
|
Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
Chang Ho Ahn, Soo Lim
J Stroke. 2019;21(2):139-150. Published online 2019 May 31 DOI: https://doi.org/10.5853/jos.2019.00038
|
|
Citations to this article as recorded by
 Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
André J. Scheen
Diabetes Epidemiology and Management.2024; 13: 100179. CrossRef Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
Ji Soo Kim, Gyeongsil Lee, Kyung-Il Park, Seung-Won Oh
Diabetes & Metabolism Journal.2024; 48(2): 312. CrossRef Amorfrutin B Protects Mouse Brain Neurons from Hypoxia/Ischemia by Inhibiting Apoptosis and Autophagy Processes Through Gene Methylation- and miRNA-Dependent Regulation
Karolina Przepiórska, Agnieszka Wnuk, Cordian Beyer, Małgorzata Kajta
Molecular Neurobiology.2023; 60(2): 576. CrossRef Hyperglycaemic Metabolic Complications of Ischemic Brain: Current
Therapeutics, Anti-Diabetics and Stem Cell Therapy
Vishal Chavda, Snehal Patel
CNS & Neurological Disorders - Drug Targets.2023; 22(6): 832. CrossRef Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André J. Scheen
Diabetes & Metabolism.2023; 49(5): 101474. CrossRef Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Sian A. Bradley, Kevin J. Spring, Roy G. Beran, Dimitrios Chatzis, Murray C. Killingsworth, Sonu M. M. Bhaskar
Diabetes/Metabolism Research and Reviews.2022;[Epub] CrossRef
|